189 related articles for article (PubMed ID: 32923124)
1. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
[TBL] [Abstract][Full Text] [Related]
2. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
Rodríguez PC; Rodríguez G; González G; Lage A
MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
[TBL] [Abstract][Full Text] [Related]
3. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
[TBL] [Abstract][Full Text] [Related]
4. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
5. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
[TBL] [Abstract][Full Text] [Related]
6. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
[TBL] [Abstract][Full Text] [Related]
7. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
[TBL] [Abstract][Full Text] [Related]
8. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
[TBL] [Abstract][Full Text] [Related]
9. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.
Saavedra D; Crombet T
Front Immunol; 2017; 8():269. PubMed ID: 28348561
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
Ruiz R; Hunis B; Raez LE
Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
[TBL] [Abstract][Full Text] [Related]
11. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF.
Fernández Lorente A; Acosta Brooks S; Neninger Vinageras E; Barroso Alvarez Mdel C; Wilkinson Brito B; Troche Concepción M; Martínez Pérez LB; Viada González CE; Crespo Diaz T; Casacó Parada AR
World J Surg Oncol; 2013 Oct; 11():275. PubMed ID: 24127898
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of CIMAvax-EGF administered in community polyclinics.
Ortiz Carrodeguas RA; Lorenzo Monteagudo G; Guerra Chaviano PP; Álvarez Montané I; Salomón Saldívar EE; Lobaina Lambert L; Camacho Sosa K; Bermúdez Pino R; Blanco Mustelier P; Valdés Rodríguez E; González Piloto S; Guerra de la Vega A; Valdés Sánchez L; Montes De Santis A; Parra Zabala J; Viada González C; Calvo Aguilera N; Saavedra Hernández D; Santos Morales O; Crombet Ramos T
Front Oncol; 2023; 13():1287902. PubMed ID: 38304035
[TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.
Rodriguez PC; Neninger E; García B; Popa X; Viada C; Luaces P; González G; Lage A; Montero E; Crombet T
J Immune Based Ther Vaccines; 2011 Oct; 9():7. PubMed ID: 22024351
[TBL] [Abstract][Full Text] [Related]
14. Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC.
Rosell R; Neninger E; Nicolson M; Huber RM; Thongprasert S; Parikh PM; D'Hondt E
J Thorac Oncol; 2016 Nov; 11(11):1954-1961. PubMed ID: 27566188
[TBL] [Abstract][Full Text] [Related]
15. [Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer].
Zhang JY; Zhu L; Yang HK; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Jun; 40(3):411-414. PubMed ID: 29978802
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
Xing P; Wang H; Yang S; Han X; Sun Y; Shi Y
BMC Immunol; 2018 Apr; 19(1):14. PubMed ID: 29661145
[TBL] [Abstract][Full Text] [Related]
17. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
Evans R; Lee K; Wallace PK; Reid M; Muhitch J; Dozier A; Mesa C; Luaces PL; Santos-Morales O; Groman A; Cedeno C; Cinquino A; Fisher DT; Puzanov I; Opyrchal M; Fountzilas C; Dai T; Ernstoff M; Attwood K; Hutson A; Johnson C; Mazorra Z; Saavedra D; Leon K; Lage A; Crombet T; Dy GK
Front Oncol; 2022; 12():958043. PubMed ID: 35992783
[TBL] [Abstract][Full Text] [Related]
18. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial.
Ramos TC; Vinageras EN; Ferrer MC; Verdecia BG; Rupalé IL; Pérez LM; Marinello GG; Rodríguez RP; Dávila AL
Cancer Biol Ther; 2006 Feb; 5(2):145-9. PubMed ID: 16357522
[TBL] [Abstract][Full Text] [Related]
19. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer.
Neninger E; Verdecia BG; Crombet T; Viada C; Pereda S; Leonard I; Mazorra Z; Fleites G; González M; Wilkinson B; González G; Lage A
J Immunother; 2009 Jan; 32(1):92-9. PubMed ID: 19307998
[TBL] [Abstract][Full Text] [Related]
20. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A
BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
